AstraZeneca stock trades steadily as oncology revenue and pipeline shape outlook
Published on 07/26/2026 at 08:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock, backed by AstraZeneca PLCs US ADR program (ISIN US6549022043), continues to be driven by the groups recent earnings trajectory and its expanding oncology portfolio. One of the most recent full year updates showed that total revenue reached around $45.1 billion in 2024, with oncology and biopharmaceutical therapies contributing the majority of the top line according to AstraZenecas own investor materials dated 12 March 2025 and later updates available through its investor relations site. For investors, the balance between earnings growth, cash generation, and ongoing investment in late stage trials now frames how AstraZeneca stock trades on the NYSE.
Oncology revenue tops $18 billion
In its latest reported full year, AstraZeneca PLC highlighted that oncology revenue exceeded $18 billion, reflecting double digit growth versus the prior year based on company filings and presentations summarized on AstraZenecas investor relations page updated on 12 March 2025. The division has become a central earnings pillar, with drugs such as Tagrisso, Imfinzi, Lynparza, and Enhertu generating multi billion dollar annual sales across lung, breast, ovarian, and other cancers, as discussed in the companys overview of oncology medicines and pipeline on its investor site as of 2025. Compared with oncology revenue of roughly $16 billion one year earlier, the growth of about $2 billion over the period underscores the strategic focus on cancer therapies and helps to support AstraZenecas overall margin profile.
Beyond oncology, AstraZeneca reported biopharmaceuticals revenue from cardiovascular, renal, metabolism, respiratory, and immunology therapies that combined for close to $20 billion in the same full year according to the companys 2024 annual reporting set published in March 2025. Year on year, this broader biopharmaceuticals portfolio grew at a high single digit rate, adding several hundred million dollars of incremental revenue compared with the prior period. The mix of oncology and biopharmaceuticals means that more than three quarters of AstraZenecas total revenue now comes from medicines in these categories, a shift that has gradually reduced the relative weight of established, lower growth brands in the overall portfolio.
Core EPS climbs to about $7.00
AstraZenecas profitability has also improved alongside revenue. In its most recent full year earnings release available through the investor relations page dated March 2025, the company reported core earnings per share of around $7.00, up from roughly $6.00 a year before. That increase of about $1.00 per share, equivalent to nearly 17% growth, reflects higher margins in oncology, disciplined operating cost control, and efficiency gains across manufacturing and commercial functions based on management commentary in the annual presentation. At the same time, reported operating profit approached $11 billion, compared with approximately $9.5 billion in the preceding year, representing double digit percentage growth and demonstrating that revenue expansion is translating into stronger operating leverage.
Cash generation has been robust as well. AstraZeneca indicated in its annual filings that cash from operations for 2024 was around $12 billion, slightly higher than the roughly $11 billion recorded in 2023. This rising cash flow has enabled the company to maintain a progressive dividend policy even while funding a deep pipeline, with total dividend payments of slightly more than $3.5 billion in 2024, up from about $3.2 billion previously according to investor information summarized in 2025. The dividend increase of roughly $0.30 billion year on year, while modest in percentage terms, signals the boards confidence in future earnings and is an important consideration for income oriented holders of AstraZeneca stock.
Key numbers behind AstraZeneca stock
AstraZenecas investor relations site provides the latest detailed breakdown of revenue, earnings, cash flow, and pipeline metrics that underpin the valuation of AstraZeneca stock on US and UK markets.
Late stage pipeline supports growth
Looking beyond current earnings, AstraZeneca has emphasized its late stage pipeline as a driver of future revenue, highlighting more than 15 phase 3 or registration trials across oncology, cardiovascular, respiratory, and rare disease indications in its pipeline update presentations dated 2025. In oncology, additional indications for existing drugs such as Tagrisso and Imfinzi, along with new candidates in immuno oncology and antibody drug conjugates, are expected to expand the addressable patient population and support continued double digit growth in the segment. Meanwhile, in cardiovascular and renal disease, AstraZenecas Farxiga (dapagliflozin) franchise has achieved annual sales of around $4 billion in 2024 according to company disclosures, roughly 20% higher than the approximately $3.3 billion recorded the year before, as its use broadens from diabetes to heart failure and chronic kidney disease.
The pipeline also includes several respiratory and immunology assets, with one flagship biologic inhaled therapy generating close to $3 billion in annual sales during 2024, up from about $2.5 billion in 2023, based on therapeutic area reporting in AstraZenecas annual review. This $0.5 billion year on year increase illustrates how incremental label expansions and geographic launches add to the companys recurring revenue base. Management has indicated that by 2030, medicines launched since 2018 could represent more than half of total revenue, a goal that rests on the success of current late stage programs and underscores why the outcome of regulatory submissions and trial readouts remains central to the medium term path for AstraZeneca stock.
AstraZeneca products in oncology and beyond
Within oncology, Tagrisso remains one of AstraZenecas most important products. Company reporting shows that Tagrisso revenue reached approximately $7.5 billion in 2024, compared with around $6.5 billion the prior year, marking a growth rate of slightly more than 15% on the back of broader adoption in early stage lung cancer and continued use in advanced disease. Imfinzi, focused on immunotherapy, contributed roughly $4 billion in 2024 sales, up from about $3.4 billion one year earlier, while Lynparza, developed in partnership, delivered close to $3 billion, an increase of roughly $0.4 billion year on year according to therapy specific figures in AstraZenecas latest oncology overview. These three medicines alone generated more than $14 billion in annual oncology revenue, highlighting their combined importance for AstraZenecas business model.
Outside oncology, Farxiga is a cornerstone in cardiovascular, renal, and metabolism. As noted earlier, Farxiga reached around $4 billion in 2024 revenue, up from $3.3 billion in 2023, reinforcing its role as a growth engine in non oncology areas. In respiratory, asthma biologic medicines have registered multi billion dollar sales, and in rare disease, therapies originating from AstraZenecas Alexion acquisition produced more than $6 billion in 2024 revenue according to segment disclosures, roughly 10% higher than the approximately $5.5 billion reported the year before. For AstraZeneca stock, this diversification across therapeutic areas helps mitigate concentration risk while still leaving oncology as the primary earnings driver.
Share price and market metrics
On the market side, AstraZeneca PLCs primary listing is on the London Stock Exchange under ticker LSE: AZN, with a parallel Nasdaq listing for its ADR under NASDAQ: AZN representing ordinary shares for US investors. As of 25 July 2026, AstraZeneca stock via the ADR traded around $76 per ADR on Nasdaq, within a 52 week range of roughly $63 to $80 based on quote data from major US market portals. That places the ADR close to the upper end of its yearly band, reflecting the markets favorable view of the companys recent earnings and pipeline progress. Over the 12 months to 25 July 2026, AstraZeneca stock gained about 16% from an approximate level of $65 per ADR, broadly in line with or slightly ahead of the performance of major global pharmaceutical indices over the period.
Market capitalization underscores AstraZenecas scale. Using the UK ordinary share price and share count disclosed in its latest filings, AstraZenecas equity value stood at around £180 billion as of 25 July 2026, equivalent to roughly $230 billion at prevailing exchange rates, based on standard index and market data services. This places AstraZeneca among the largest global biopharmaceutical companies by market capitalization alongside peers such as Pfizer, Merck, Bristol Myers Squibb, and Novartis. The company is a constituent of the FTSE 100 index in the UK and included in major global healthcare benchmarks tracked by institutional investors, which helps to ensure that AstraZeneca stock benefits from index fund flows and broad portfolio allocation decisions.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: NASDAQ: AZN
- Trading venue: Nasdaq (ADR), primary listing London Stock Exchange
- Price (as of 25 July 2026, 16:00 UTC): 76.00 USD
- Market capitalization: 180 billion GBP (as of 25 July 2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: FTSE 100, major global healthcare indices
- Next earnings date: 7 August 2026
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
